Sandostatin-LAR: This long-acting drug (Novartis) is commonly used for control of symptoms and may also play a role in slowing disease progression. The drug is injected in the gluteal muscle and there is a specific mixing technique which must be followed to ensure that the patient receives the full dose of the drug in an active form. You should be able to monitor this process at your doctor's office. For more information, including payment assistance programs contact Novartis Patient Assistance.
Somatuline Depot (Lanreotide): Somatuline Depot, a somatostatin analogue, is the first therapy approved by the FDA in the U.S. for the treatment of patients with locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (Dec 2014). For more information, click here. For information regarding coverage, access, and reimbursement, contact Ipsen Cares.
Sandostatin-LAR vs Lanreotide: Information comparing these two drugs on Ronny Allan's Blog.